Phase I of RG3502 in Combination With RG1273
Phase 1
- Conditions
- HER2 positive Breast Cancer
- Registration Number
- JPRN-jRCT2080221197
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 6
Inclusion Criteria
Inoperable advanced or recurrent breast cancer;
HER2-positive (FISH + or IHC 3+);
ECOG PS :0-2
Exclusion Criteria
Clinically significant cardiac disease;
Grade 3 or higher Hypersensitivity for trastuzumab
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method